PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 137 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 0.37 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $20,095,442,000 | +100593.7% | 3,948,024 | 0.0% | 0.13% | -3.6% |
| Q3 2019 | $19,957,000 | -18.1% | 3,948,024 | 0.0% | 0.14% | -16.8% |
| Q2 2019 | $24,359,000 | +33.0% | 3,948,024 | 0.0% | 0.17% | +28.5% |
| Q1 2019 | $18,318,000 | +10.5% | 3,948,024 | 0.0% | 0.13% | -7.1% |
| Q4 2018 | $16,582,000 | -33.0% | 3,948,024 | 0.0% | 0.14% | -20.9% |
| Q3 2018 | $24,745,000 | -22.0% | 3,948,024 | 0.0% | 0.18% | -29.2% |
| Q2 2018 | $31,742,000 | +13.1% | 3,948,024 | 0.0% | 0.25% | +14.7% |
| Q1 2018 | $28,070,000 | +28.8% | 3,948,024 | +7.8% | 0.22% | -6.0% |
| Q4 2017 | $21,790,000 | – | 3,662,118 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
| Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
| FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
| J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
| EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
| Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |